03:57 AM EDT, 07/05/2024 (MT Newswires) -- AbbVie ( ABBV ) expects its Q2 adjusted earnings to take a $0.52 per-share hit from acquired in-process research and development and milestones expense of $937 million on a pre-tax basis, according to a Wednesday regulatory filing.

The company expects Q2 adjusted EPS of $2.53 to $2.57, including the impact, the filing showed. Analysts surveyed by Capital IQ expect normalized EPS of $3.06.

For full-year 2024, AbbVie ( ABBV ) now expects adjusted EPS of $10.61 to $10.81, compared with its prior guidance range of $11.13 to $11.33. Analysts polled by Capital IQ expect $11.25.

Price: 164.00, Change: +0.16, Percent Change: +0.10